FDA starts review of Roche’s multiple sclerosis pill
The FDA previously hadn't ever accepted an application of a drug like fenebrutinib in two major forms of MS.
Useful takeaways from this story.
The FDA previously hadn't ever accepted an application of a drug like fenebrutinib in two major forms of MS.
The FDA previously hadn't ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche's program.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
The FDA previously hadn't ever accepted an application of a drug like fenebrutinib in two major forms of MS. Safety questions still hang over Roche's program.
Details worth keeping
Safety questions still hang over Roche's program.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.